Document:

EX-10.2

	
					
	 
	 
	 
	 
	Exhibit 10.2

July 7, 2015

Mr. Paul Marciano
Guess?, Inc.
1444 South Alameda Street
Los Angeles, California  90021

Re:    Amendment to Employment Agreement

Dear Paul:

Reference is made to that certain Employment Agreement entered into by and between you and Guess?, Inc., a Delaware corporation (the “Company”), dated July 11, 2013 (your “Employment Agreement”).  This letter amendment (this “Amendment”) sets forth the agreement by and between you and the Company as follows. 
As you are aware, the Company is contemplating entering into an employment agreement with Victor Herrero to serve as Chief Executive Officer of the Company (the “Herrero Employment Agreement”).  You have had an opportunity to review a copy of the Herrero Employment Agreement.
Subject to Mr. Herrero’s commencement of active employment with the Company or one of its subsidiaries, Mr. Herrero will become the Company’s Chief Executive Officer effective as of August 1, 2015 (the “Effective Time”).  At the Effective Time, you will transition to being the Company’s Executive Chairman and Chief Creative Officer and will no longer serve as the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors.  For purposes of clarity, you will remain an employee of the Company in connection with such transition.  Your Employment Agreement is amended, effective upon the Effective Time, by replacing each reference to “Chief Executive Officer” in your Employment Agreement with “Executive Chairman and Chief Creative Officer.” 
Effective February 1, 2016, your annual rate of base salary will be $570,000.  Your annual cash bonus each fiscal year, beginning with fiscal 2017, will be determined with reference to your new base salary level.  The grant date fair value of your annual equity awards from the Company, beginning with your equity awards granted in fiscal 2017, will similarly be reduced compared to your historic levels while serving as Chief Executive Officer.  
For purposes of determining your benefits under the Guess?, Inc. Supplemental Executive Retirement Plan, as amended (the “SERP”), if you retire from the Company after January 31, 2016, your “Average Compensation” for purposes of the SERP will be determined as of January 31, 2016 as though you retired from the Company at that time and taking into account the July 2013 SERP amendment to cap your annual “Compensation” considered for such purposes.

You agree that the Company’s entering into the Herrero Employment Agreement, its employment of Mr. Herrero pursuant to the terms and conditions of the Herrero Employment Agreement, and your transition to being the Company’s Executive Chairman and Chief Creative Officer as referenced above with the compensation adjustments provided for above will not give rise to “Good Reason” under your Employment Agreement and will not constitute a breach by the Company of any provision of your Employment Agreement.  
Your Employment Agreement and the SERP (each as modified by this Amendment) otherwise remain in full force and effect.  This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
You and the Company have caused this Amendment to be duly executed and delivered on the day and year first above written.
	
		
	Guess?, Inc.

	a Delaware corporation

	 
	 

	 
	/s/ SANDEEP REDDY

	By:
	Sandeep Reddy

	Its:
	Chief Financial Officer

	 
	 

	 
	 

	 
	/s/ PAUL MARCIANO

	 
	Paul MarcianoEXHIBIT 4.22

 

FIRST AMENDMENT TO THE

PEREGRINE PHARMACEUTICALS, INC.

2005 STOCK INCENTIVE PLAN

 

Peregrine Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), previously established the Peregrine Pharmaceuticals, Inc. 2005 Stock
Incentive Plan (the “2005 Plan”). The Plan was approved by the Company’s stockholders at the Company’s
2005 Annual Meeting on October 25, 2005. At a duly noticed meeting held on April 24, 2015, the Board of Directors of the Company,
and the Compensation Committee of the Board, approved and adopted the following amendment to the 2005 Plan.

 

1.     Clause C.1.(i) of Section I (OPTION TERMS) of ARTICLE TWO of the 2005 Plan is hereby amended and restated in its entirety to read
as follows:

 

(i) Any option outstanding at
the time of the Optionee’s cessation of Service for any reason shall remain exercisable for such period of time thereafter
as shall be determined by the Plan Administrator and set forth in the documents evidencing the option, provided no such option
shall be exercisable after the expiration of the option term.

 

2.     Except as amended by this First Amendment, all other terms of the 2005 Plan shall remain unmodified and in full force and effect.

 

IN WITNESS WHEREOF,
the Company has caused this First Amendment to be executed as of this 24th day of April, 2015.

 

The Company:

 

PEREGRINE PHARMACEUTICALS,
INC.

a Delaware corporation

 

 

By: /s/ Paul Lytle                       

Name: Paul Lytle

Title:   Chief Financial OfficerEXHIBIT 4.23

 

FIRST AMENDMENT TO THE

PEREGRINE PHARMACEUTICALS, INC.

2009 STOCK INCENTIVE PLAN

 

Peregrine Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), previously established the Peregrine Pharmaceuticals, Inc. 2009 Stock
Incentive Plan (the “2009 Plan”). The Plan was approved by the Company’s stockholders at the Company’s
2009 Annual Meeting on October 22, 2009. At a duly noticed meeting held on April 24, 2015, the Board of Directors of the Company,
and the Compensation Committee of the Board, approved and adopted the following amendment to the 2009 Plan.

 

1.     Clause C.1.(i) of Section I (OPTION TERMS) of ARTICLE TWO of the 2009 Plan is hereby amended and restated in its entirety to read
as follows:

 

(i) Any option outstanding at
the time of the Optionee’s cessation of Service for any reason shall remain exercisable for such period of time thereafter
as shall be determined by the Plan Administrator and set forth in the documents evidencing the option, provided no such option
shall be exercisable after the expiration of the option term.

 

2.     Except as amended by this First Amendment, all other terms of the 2009 Plan shall remain unmodified and in full force and effect.

 

IN WITNESS WHEREOF,
the Company has caused this First Amendment to be executed as of this 24th day of April, 2015.

 

 

The Company:

 

PEREGRINE PHARMACEUTICALS,
INC.

a Delaware corporation

 

 

By: /s/ Paul Lytle                       

Name: Paul Lytle

Title:   Chief Financial OfficerEXHIBIT 4.24

 

THIRD AMENDMENT TO THE

PEREGRINE PHARMACEUTICALS, INC.

2011 STOCK INCENTIVE PLAN

 

Peregrine Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), previously established the Peregrine Pharmaceuticals, Inc. 2011 Stock
Incentive Plan, as amended (the “2011 Plan”). The Plan was approved by the Company’s stockholders at the Company’s
2011 Annual Meeting on October 20, 2011. At a duly noticed meeting held on April 24, 2015, the Board of Directors of the Company,
and the Compensation Committee of the Board, approved and adopted the following amendment to the 2011 Plan.

 

1.     Paragraph (iii) of Section 6.1(f) (Lapse of Option) of ARTICLE 6 of the 2011 Plan is hereby amended and restated in its entirety
to read as follows:

 

(iii) If the Participant
has a Termination of Employment (or Service) on account of Disability or death before the Option lapses pursuant to paragraph (i)
or (ii) above, the Option shall lapse, unless otherwise exercised, on the earlier of (a) the scheduled expiration date of the Option;
or (b), unless otherwise provided in the Award Agreement, 12 months after the date of the Participant’s Termination of Employment
(or Service) on account of Disability or death. Upon the Participant’s Disability or death, any Options exercisable at the
Participant’s Disability or death may be exercised by the Participant’s legal representative or representatives, by
the person or persons entitled to do so pursuant to the Participant’s last will and testament, or, if the Participant fails
to make testamentary disposition of such Option or dies intestate, by the person or persons entitled to receive the Option pursuant
to the laws of descent and distribution.

 

2.     Except as amended by this Third Amendment, all other terms of the 2011 Plan shall remain unmodified and in full force and effect.

 

IN WITNESS WHEREOF,
the Company has caused this First Amendment to be executed as of this 24th day of April, 2015.

 

The Company:

 

PEREGRINE PHARMACEUTICALS,
INC.

a Delaware corporation

 

 

By: /s/ Paul Lytle                       

Name: Paul Lytle

Title:   Chief Financial OfficerEXHIBIT 4.25

 

FORM OF AMENDMENT TO NON-QUALIFIED STOCK
OPTION AGREEMENT

UNDER THE PEREGRINE PHARMACEUTICALS, INC.

2005 STOCK INCENTIVE PLAN

(NON-EMPLOYEE DIRECTORS) 

 

This Amendment (“Amendment”)
to Non-Qualified Stock Option Agreement (the “Agreement”) dated as of __________, is between Peregrine Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and ________, (the “Optionee”).

 

WHEREAS, on ___________,
Optionee was awarded an option to purchase ________ shares of the Company’s common stock pursuant to the Peregrine Pharmaceuticals,
Inc. 2005 Stock Incentive Plan, as amended from time to time (the “Plan”), as set forth in the Award Agreement;

 

WHEREAS, capitalized terms
used but not defined herein shall have the meanings ascribed to them in the Plan;

 

WHEREAS, pursuant to clause
C.2.(i) of Section 1 of Article Two of the Plan, the Plan Administrator (which means the Compensation Committee of the Board) has
the authority to extend the period of time for which an outstanding option is to remain exercisable following an Optionee’s
cessation of Service;

 

WHEREAS, on April 24, 2015,
the Compensation Committee of the Company’s Board of Directors approved an amendment to all outstanding options to non-employee
members of the Company’s Board of Directors extending the exercise period following a Termination of Employment (or Service)
for any reason to two (2) years (the “Extended Exercise Period”); and

 

WHEREAS, Company and Optionee
desire to enter into this Amendment in order to restate Section 7 of the Agreement to reflect the Extended Exercise Period.

 

NOW, THEREFORE, the parties
hereto hereby agree as follows:

 

1.            Section
5 of the Agreement is hereby amended and restated in its entirety as follows:

 

“5. Termination of
Employment; Death. Upon termination of Optionee’s employment with or status as a consultant to, the Company for any
reason, the Options will immediately terminate and expire, except as provided in paragraphs (a) or (b) of this Section 5.

 

(a) If
Optionee resigns as an employee of, or consultant to, the Company with the Company's prior written consent, or if the Company
terminates Optionee's employment by the Company without Cause (as defined herein), the Option will be exercisable but only to
the extent it was exercisable at the time of such termination or resignation and only until the earlier of the
expiration date of the Option, determined pursuant to Section 2 of this Agreement, or the expiration of two (2) years
following such termination or resignation.

 

(b) If
Optionee dies or becomes Permanently Disabled while employed by, or rendering services as a consultant to, the Company or
after Optionee's employment or status as a consultant to the Company terminates but during a period in which the
Option is exercisable pursuant to paragraph (a) of this Section 5, the Option will be exercisable but only to the
extent it was exercisable at the time of death and only until the earlier of the expiration date of the Option, determined
pursuant to Section 2 of this Agreement, or the expiration of two (2) years following the date of Optionee's death or the
date Optionee becomes Permanently Disabled.”

 

2.            The remaining terms and conditions of
the Agreement shall survive this Amendment and will continue in full force and effect.

 

IN WITNESS WHEREOF, the
parties hereto have executed this Amendment as of the date and year first written above.

 

PEREGRINE PHARMACEUTICALS,
INC.

 

 

 

By:________________________________

 

 

 

OPTIONEE:

 

 

__________________________________

Signature

 

Name:____________________________

 

Social Security Number:

 

_________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]